Shannon Brisbin, PA
Physician Assistant · Huntington, INNPI 1972156990
Payments from drug & device makers
Across 115 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$339
- Novo Nordisk$261
- AstraZeneca$246
- Lilly USA, LLC$222
- Boehringer Ingelheim$187
- Axsome Therapeutics, Inc.$104
- plus $717 from 20 others
What the payments were for
- Food & beverage$2,076100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $339 |
| Novo Nordisk | 14 | $261 |
| AstraZeneca | 8 | $246 |
| Lilly USA, LLC | 17 | $222 |
| Boehringer Ingelheim | 11 | $187 |
| Axsome Therapeutics, Inc. | 5 | $104 |
| Abbott | 4 | $77 |
| Bayer | 4 | $63 |
| Shield Therapeutics Inc | 2 | $59 |
| Pfizer | 3 | $59 |
| Astellas Pharma US Inc | 2 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Dynavax Technologies Corporation | 2 | $41 |
| GSK | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Exact Sciences | 2 | $34 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $25 |
| Johnson & Johnson | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Merck | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Amgen | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$125
How this compares
$2,076 in reported general payments places this provider in the 85th percentile of 1,955 physician assistant providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $93,379 |
| JardianceEmpagliflozin | 30 | $37,843 |
| JanuviaSitagliptin Phosphate | 32 | $37,841 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $37,563 |
| RybelsusSemaglutide | 20 | $37,433 |
| EliquisApixaban | 33 | $35,933 |
| MounjaroTirzepatide | 16 | $28,212 |
| XareltoRivaroxaban | 15 | $24,085 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $12,598 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $9,390 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $7,880 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,681 |
| Humalog Kwikpen U-100Insulin Lispro | 20 | $6,584 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 163 | $3,088 |
| Atorvastatin Calcium | 313 | $2,544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $261 | $130,81279 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $41 | $56,84379 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $187 | $47,23341 claims |
| MerckJanuvia | $15 | $37,84132 claims |
| PfizerEliquis | $59 | $35,93333 claims |
| Lilly USA, LLCMounjaro | $222 | $28,21216 claims |
| Johnson & JohnsonXarelto | $22 | $24,08515 claims |
| AbbVieSynthroid | $339 | $2,38232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,955 physician assistant providers in Indiana.
Other physician assistant in Huntington
- Kristen GumpfCarmel$142K
- Andrew NordIndianapolis$47K
- Qun Ming ZhangIndianapolis$28K
- Lauren HoweMunster$28K
- A FergusonFort Wayne$22K
- Jacquelyn BeemerFort Wayne$21K
- Lindsay YoderIndianapolis$21K
- Eryn GormanClinton$18K
- Audrey HewittBloomington$17K
- Mackenzie LawsonIndianapolis$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.